Axsome Therapeutics, Inc.AXSMEarnings & Financial Report
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM Q1 FY2026 Key Financial Metrics
Revenue
$191.2M
Gross Profit
N/A
Operating Profit
$-63.4M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
-33.1%
Net Margin
N/A
YoY Growth
57.4%
Axsome Therapeutics, Inc. Q1 FY2026 Financial Summary
Axsome Therapeutics, Inc. reported revenue of $191.2M (up 57.4% YoY) for Q1 FY2026, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $191.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | -33.1% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Axsome Therapeutics, Inc. Q1 FY2026 revenue of $191.2M breaks down across 2 segments, led by Product sales, net at $189.4M (99.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product sales, net | $189.4M | 99.1% |
| Royalty revenue and milestone revenue | $1.8M | 0.9% |
Axsome Therapeutics, Inc. Annual Revenue by Year
Axsome Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $638.5M).
Axsome Therapeutics, Inc. Quarterly Revenue & Net Profit History
Axsome Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $191.2M | +57.4% | N/A | N/A |
| Q4 FY2025 | $196.0M | +65.0% | $-28.6M | -14.6% |
| Q3 FY2025 | $171.0M | +63.2% | $-47.2M | -27.6% |
| Q2 FY2025 | $150.0M | +72.1% | $-48.0M | -32.0% |
| Q1 FY2025 | $121.5M | +62.0% | $-59.4M | -48.9% |
| Q4 FY2024 | $118.8M | +66.0% | $-74.9M | -63.1% |
| Q3 FY2024 | $104.8M | +81.3% | $-64.6M | -61.7% |
| Q2 FY2024 | $87.2M | +86.7% | $-79.3M | -91.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $87.2M | $104.8M | $118.8M | $121.5M | $150.0M | $171.0M | $196.0M | $191.2M |
| YoY Growth | 86.7% | 81.3% | 66.0% | 62.0% | 72.1% | 63.2% | 65.0% | 57.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $548.2M | $561.5M | $568.5M | $596.7M | $639.8M | $669.3M | $689.8M | $713.6M |
| Liabilities | $445.4M | $468.6M | $511.5M | $543.5M | $566.7M | $595.5M | $601.5M | $659.0M |
| Equity | $102.9M | $92.9M | $57.0M | $53.2M | $73.1M | $73.7M | $88.3M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-30.1M | $-18.6M | $-26.2M | $-43.4M | $-32.4M | $1.0M | $-18.7M |